Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe version history now displays a new revision entry (v3.5.5) and removes the preceding revision (v3.5.4), reflecting an updated record meta.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRecord History now includes added sections for Adverse Events, Outcome Measures, Participant Flow, and References. A new version entry dated 2026-05-12 indicates updated content in the study record.SummaryDifference0.8%

- Check47 days agoChange DetectedThe page’s revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a site or interface release rather than substantive trial-record changes.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded revision v3.5.2 and removed revision v3.5.0 from the study record history.SummaryDifference0.1%

- Check83 days agoChange DetectedA new revision entry v3.5.0 has been added and the previous entry v3.4.3 has been removed.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded revision v3.4.3 and removed revision v3.4.2 in the record history.SummaryDifference0.1%

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.